Interim results from a Phase Ib trial show that gene therapy may reduce the need for medication in patients with Parkinson’s disease refractory to levodopa. The investigational therapy is designed…
read moreHow close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…
read moreSecondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…
read moreSmartphone-based, high-yield active and passive self-monitoring of multiple sclerosis (MS) may enhance clinical disease assessments when compared to conventional methods for detecting subtle progressive clinical changes, according to a study…
read moreKey symptoms of schizophrenia, including hallucinations, hyperactivity and impaired memory, could be caused by desynchronised cells in the brain, recent research published in Nature Neuroscience has revealed. The authors investigated…
read moreThe US FDA has approved a new humanised monoclonal antibody for migraine prevention in adults. Fremanezumab-vfrm – under the brand name AJOVYTM (Teva Pharmaceuticals) – prevents the interaction between calcitonin…
read moreRoutine retinal tests performed by opticians could help to identify those at risk of developing dementia, a new study reports. The scans – normally used to evaluate the integrity of…
read moreDeep brain stimulation (DBS) could slow the progression of tremors in Parkinson’s disease (PD), according to new data from a pilot trial.1 Researchers at the Vanderbilt University Medical Center (Nashville,…
read moreAt the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…
read moreCutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…
read more- 1
- 2